Sanofi and GSK have announced positive results from the trial of their adjuvanted bivalent D614 and Beta (B.1.351) Covid-19 vaccine candidate.
In the placebo-controlled trial, which was carried out in a high Omicron variant circulation environment, the Beta-containing vaccine candidate demonstrated a favourable safety and tolerability profile.
Go deeper with GlobalData
Earlier this month, Sanofi reported positive data from two studies that were conducted with its new next-generation Covid-19 booster vaccine candidate modelled on the Beta variant antigen and including the pandemic adjuvant of GSK.
The company will submit the data supporting this booster vaccine to regulatory authorities.
GSK Vaccines president Roger Connor said: “These positive data show efficacy of our protein-based, bivalent adjuvanted vaccine candidate in an environment of high Omicron variant circulation.
“Our vaccine candidate has the potential to make an important contribution to public health as the pandemic evolves further. We are looking forward to the discussions with regulatory authorities with the aim of making our vaccine candidate available later this year.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataStage two of the Phase III Covid-19 vaccine trial VAT08 enrolled more than 13,000 subjects aged 18 years and older to evaluate the Sanofi-GSK vaccine candidate.
Throughout the trial’s Stage 1 and Stage 2, the Sanofi-GSK vaccine showed a favourable safety as well as tolerability profile.
Sanofi Vaccines executive vice-president Thomas Triomphe said: “With the immunogenicity data from our Beta-booster vaccine, they support our belief that, in a largely seropositive world, a next-generation Beta booster vaccine could provide protection against variants like Omicron.”
As part of a partnership between the two companies, Sanofi provides its recombinant antigen and will be the holder of the marketing authorisation while GSK contributes with its adjuvant.
